Skip to main content
. Author manuscript; available in PMC: 2022 Dec 22.
Published in final edited form as: Sci Transl Med. 2022 Jun 22;14(650):eabo4474. doi: 10.1126/scitranslmed.abo4474

Fig. 3. Independent validation of PLS-NAFLD in HCC-naïve and HCC-experienced patients with NAFLD.

Fig. 3.

(A) Overview of tissue sampling and clinical follow-up in the tissue validation set 1. (B) Expression of PLS-NAFLD genes and clinico-histological and genetic features in tissue validation set 1. (C) Prognostic association of PLS-NAFLD with incident HCC in tissue validation set 1. (D) Longitudinal changes in PLS-NAFLD-based HCC risk measured by combined enrichment score (CES) and clinico-histological features and laboratory tests between the serial biopsies. (E) Prognostic association of improved PLS-NAFLD. (F) Time-dependent AUROC of improved PLS-NAFLD and regressed fibrosis (decreased F-stage). (G) Expression of PLS-NAFLD genes with clinico-histological and genetic features in tissue validation set 2. (H) Prognostic association of PLS-NAFLD in tissue validation set 2.